Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients.
about
25 Years of Contrast-Enhanced MRI: Developments, Current Challenges and Future PerspectivesAdvances in Magnetic Resonance Imaging Contrast Agents for Biomarker DetectionNuclear magnetic resonance imaging in medicineGadolinium enhanced magnetic resonance imaging in the diagnosis of anterior visual pathway meningiomas.Nuclear magnetic relaxation dispersion profiles of aqueous solutions of a series of Gd(NOTA) analogs.Evaluation of polyaza macrocyclic methylene phosphonate chelates of Gd3+ ions as MRI contrast agents.Interaction of Gd-DTPA with phosphate and phosphite: toward the reaction intermediate in nephrogenic systemic fibrosis.Amplification strategies in MR imaging: activation and accumulation of sensing contrast agents (SCAs).MRI detection of paramagnetic chemical exchange effects in mice kidneys in vivo.New directions in medical imaging of cancer. Magnetic resonance methods and single photon emission computed tomography.Label-Free Microfluidic Manipulation of Particles and Cells in Magnetic Liquids.Basic principles of magnetic resonance imaging--an updateTwo-site exchange revisited: a new method for extracting exchange parameters in biological systems.Non-invasive imaging of neuroanatomical structures and neural activation with high-resolution MRI.Supratentorial tumours. Part II: Tumours of neuroglial cells.Number of inner-sphere water molecules in Gd3+ and Eu3+ complexes of DTPA-amide and -ester conjugates.Contrast-enhanced magnetic resonance imaging of tumours of the central nervous system: a clinical review.Intravascular susceptibility contrast mechanisms in tissues.Molecular MR Imaging ProbesBreast cancer imaging: a perspective for the next decade.Supratentorial tumours. Part I: General role of imaging.A Nonenhancing World Health Organization Grade II Intramedullary Spinal Ependymoma in the Conus: Case Illustration and Review of Imaging Characteristics.Contrast-enhanced cardiovascular magnetic resonance imaging of coronary vessel wall: state of art.Spatially resolved chemical reaction monitoring using magnetic resonance imaging.Contrast-enhanced MR imaging of the liver.Chelates of gadolinium and dysprosium as contrast agents for MR imaging.Abdominal imaging.Fast MR imaging techniques: impact in the abdomen.MR imaging contrast agents--what's in a name?Reduced field of view imaging using a static second-order gradient for functional MRI applications.Gadolinium-DTPA enhancement of soft tissue tumors in magnetic resonance imaging--preliminary clinical experience in five patients.Preliminary clinical trial of gadodiamide injection: a new nonionic gadolinium contrast agent for MR imaging.The magnetic properties of some materials affecting MR images.Spinal cord tumors: gadolinium-DTPA-enhanced MR imaging.Biomineral Nano-Theranostic agent for Magnetic Resonance Image Guided, Augmented Radiofrequency Ablation of Liver Tumor.Phase III clinical evaluation of Gd-HP-DO3A in head and spine disease.Novel contrast mixture improves bladder wall contrast for visualizing bladder injury.A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years.NMR changes in experimental allergic encephalomyelitis: NMR changes precede clinical and pathological events.Variations in slice shape and absorption as artifacts in the determination of tissue parameters in NMR imaging.
P2860
Q26774810-0CCC98F7-8337-49A9-BA3C-C5B0C9005304Q28830010-6CEEB988-314F-4B52-B038-754242BA7767Q30493984-8BE0FE7E-7245-47F0-A77F-C4CCA1B60876Q30502718-CA7CF107-5B88-41F5-8631-90D5A22052F9Q30833987-EDD8389F-D3F4-41E1-B44E-F735F04D40BBQ30870301-5D85B08B-30F6-435A-857F-98B91F279C14Q31048535-AE318F00-A9EF-48E8-BC68-189E4D7FFE48Q31064869-F9780066-C358-45DA-85E5-D9477BEA5642Q31131246-2C0FBE5B-9926-4114-B18C-B39A4ECC474BQ33515934-70C2AC32-7FEF-4102-9E83-FE1435726328Q33842143-F6FFC7E7-85DD-4845-A847-172CF4C992F8Q34193180-3C315450-4549-4B90-9B91-A2B50BD69DF7Q34261174-F006AB4C-20AD-4288-8F8F-71078A60E7BCQ34765860-BB336722-5AD1-48DE-A992-3B0C9C109BF5Q36406510-E268371A-C5A6-4395-B64F-7D8867CA163FQ36439709-CEA11103-F08C-4F4E-A276-9097BD61BDD7Q36479103-2E76C8F7-A023-43A6-ACAD-113668353D8EQ36743656-AE6874EA-A640-49C3-A0D8-2274251ED84FQ37079267-4D348F6A-FA68-452A-A750-14AE155E47D1Q37170246-BB7427C1-B351-4451-BB3D-DD73B4602C6FQ37204279-0A579987-ABE3-4A55-B1A1-9C10E8AE805DQ38172528-DDF8C4FE-173F-4C0F-A058-A6AC71ED6DB2Q38177865-B4DC056E-8DE8-4069-8DBB-D346C02EBE08Q38318727-D5E974A2-4D6E-421F-9F35-F537F775278FQ40689435-23A97988-40E3-4429-912A-B5A1A380F3D2Q40873073-9EF56AE4-182D-497A-9984-BE31E535BF32Q40873129-318B3477-BB8A-46F1-A8DD-152A21BA548BQ41187057-A9FE214A-6E15-4AEF-A1E6-D0C13833BDEAQ41352704-A473F143-E305-4519-969C-B098587CE78CQ43239855-944B9D4E-69DB-4C70-AA91-AD9076D05231Q43454339-AB17A4AE-A2BE-40FD-8D6B-04F5E24F6251Q44190927-A6532093-5179-4D32-B0A9-74C6227FD8CEQ45238043-8C52CE58-FE37-46C2-849D-AACC30983376Q45992167-46943BF4-9250-4A9D-8C89-0223AAE245ECQ46273981-27D9F7D3-AE14-4A9C-9AB7-BE10DDE220E6Q46585054-7CB38241-B7CD-4CFF-AF48-9A9F7C3ABBC4Q47314030-8F9A92E0-0172-4F33-867F-9E43DFB2C072Q48113624-43FBE43B-FD1B-4A23-BBFF-39D51767F460Q48222949-733390C6-A0D7-4A7E-A2AA-3A03D6FE1A8DQ48462944-50479B84-173E-4B14-B28C-9F75C00C1E60
P2860
Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
1984年學術文章
@zh-hant
name
Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients.
@en
Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients.
@nl
type
label
Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients.
@en
Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients.
@nl
prefLabel
Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients.
@en
Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients.
@nl
P2093
P356
P1476
Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients.
@en
P2093
Steiner RE
Weinmann HJ
P304
P356
10.2214/AJR.143.2.215
P407
P577
1984-08-01T00:00:00Z